Bayer, Johnson & Johnson to develop, market thrombosis drug

FRANKFURT (AP) - Bayer Healthcare, a unit of Bayer AG, said Wednesday it will develop and market a drug to treat blood clots with Johnson & Johnson in a $290-million-US deal. The drug is undergoing phase II clinical trials....More